All posts by imreal

Deep Bio Acquires MDSAP Certification, Paving the Way for Global Expansion


I am confident that passing the MDSAP audit can be a great opportunity to expand our presence in overseas markets.

Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, announced that it has been recently granted Medical Device Single Audit Program (MDSAP) certificate.

MDSAP is a unified global regulatory audit of medical device manufacturing operated by the International Medical Device Regulators Forum (IMDRF). MDSAP-certified manufacturers are considered to have satisfied the relevant requirements of the regulatory authorities participating in the program including the United States (FDA), Canada (Health Canada), Japan (MHLW), Australia (TGA), and Brazil (ANVISA).

Through the MDSAP certificate, Deep Bio demonstrated its commitment to high product quality standards and safety management. Also, it is expected that Deep Bio will be able to enter the US, Canada, Japan, Australia, and Brazil markets faster and more efficiently in the future, saving time and cost associated with Quality Management System (QMS) in each market.

“Obtaining MDSAP certification is meaningful in that our products are recognized for outstanding quality management on top of innovative technology in the global market,” said Sun Woo Kim, CEO of Deep Bio. “In particular, as these five countries account for more than half of the global medical device market, I am confident that passing the MDSAP audit can be a great opportunity to expand our presence in overseas markets. At the same time, we will make every effort to strengthen our differentiated technology through continuous product research and establish ourselves as a leader in AI-based cancer diagnostics in global markets,” added he.

Deep Bio continues to focus on not only AI diagnostics but also R&D and presenting the results in various international conferences and events. The company also continues to build its presence in the global market through overseas digital pathology solution providers in the US, Europe, and India, as well as conducting research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Center, and other top research institutions in the US.

About Deep Bio

Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. Our vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is actively engaged in the research space and participating in ongoing collaborations with top US medical centers. To learn more, visit http://www.deepbio.co.kr.

DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at US CLIA labs (500k cores in 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit http://www.deepbio.co.kr.

Share article on social media or email:

BioPlus Specialty Pharmacy Introduces the ‘BioPlus V’ Virtual Pharmacy Tool


BioPlus Specialty Pharmacy, a CarepathRx company and the preeminent specialty pharmacy in the United States, today introduced ‘BioPlus V,’ the only virtual pharmacy tool that provides comprehensive visibility for prescribers into every step of their patients’ specialty medication journey.

Built on BioPlus’ Power of 2 technology, BioPlus V enables prescribers and their office staff to break the chains of time-consuming phones, faxes, and paperwork. Prescribers can access a fast and easy digital platform to view and instantly respond to their patients’ specialty pharmacy medication orders – in real-time. From a broad overview of an entire practice or physician’s patients to a targeted, precise look of a single patient, prescribers gain instant access to expansive medication journey details. These details include information about patient onboarding, benefits investigation, prior authorizations, appeals, triage, delivery scheduling, shipping, and refills, all of which are securely and conveniently accessed beyond the constraints of phones and fax machines.

Built for Prescribers, With Prescribers

Unlike passive portal technologies designed by outsiders, BioPlus V engaged with prescribers to better understand their wants and needs through a co-creation development process. The result is a completely interactive pharmacy tool that gives prescribers exactly what they want in order to access real-time data, respond to patient therapy needs, and make actionable, patient-centered decisions to drive improved clinical outcomes.

BioPlus V’s additional real-time benefits include:

  • Ability to go from a dashboard overview to a detailed list, in just one click
  • ‘Action Required’ flagging to bring attention to refills that need an intervention by prescribers or office staff
  • Easy to find statuses for every step of the prior authorization and appeal processes
  • Continuous visibility for prescribers, including: patients requiring triage to another pharmacy, status of triage process, name of pharmacy providing continuation of care to the patient
  • Ability to drill down and view patient details pages, including patient’s orders, current authorizations, and copays, as well as shipment tracking numbers
  • Versatility to upload documentation directly to the BioPlus onboarding team

Fulfilling a Vision to Better Serve Patients

“BioPlus V fulfills the lifelong vision of Stephen Vogt, Pharm.D, BioPlus’ company founder ‘to serve patients and make the world a better place for them.’ This is why this virtual pharmacy tool is branded in his honor,” said Mark Montgomery, CEO and President of BioPlus. “Prescribers and medical office staff get total visibility into patients’ specialty medications, where they are, and everything they need to know to optimize the patient experience. Just the way Dr. Vogt intended.”

“Providers can leverage the V platform to reduce their administrative burden, spend more quality time with patients, and operate more efficiently. Using our ‘work to zero’ feature, office staff can quickly prioritize actions, discontinue reliance on outdated fax machine technology, and get back to helping patients,” said Howard Barsky, BioPlus’ Vice President of Application and Data Strategy.

BioPlus V focuses on the future of specialty pharmacy by continuously listening to the voices that matter most in healthcare: the prescriber and the patient. The company’s listening continues. In fact, the early reviews from BioPlus prescriber offices are enthusiastic about the potential of BioPlus V to change the day-to-day flow of medical offices:

“I am going to love this. I spend a lot of time emailing my rep back and forth trying to figure out where meds are and if it’s been triaged … Not having to track down papers is phenomenal!”

“We have 400-something patients on oncology therapy and it’s hard to keep track of everything. Having patients’ info all in one place makes it so much easier.”

“The ease – when a patient calls, instead of us having to take a break and look back and make a call, we can look it up easily then and there. That saves a lot of time.”

Prescribers can view a demo of BioPlus V at http://www.bioplusV.com.

About BioPlus Specialty Pharmacy

Meet the preeminent national specialty pharmacy backing up the ‘fast & easy’ promise with the Power of 2. Part of the CarepathRx family of pharmacy and medication management solutions, BioPlus offers a 2 Hour Patient Acceptance Guarantee™ so physician offices quickly know whether a referred patient is accepted for treatment. Then prescriptions are on their way with our 2 Day Ready 2 Ship™. Medication refills are an easy 2 clicks away for qualifying prescriptions.

Ranked #1 by both patients and prescribers, BioPlus provides a complete range of specialty pharmacy services for cancer, multiple sclerosis, hepatitis C, and other complex, chronic conditions. BioPlus also offers concierge-class infusion services and expertise.

For every referral received, BioPlus provides a life-saving antibiotic through our partnership with OneWorld Health. It’s part of our global vision to heal the world 2gether, helping to ensure patients across town and around the world have access to life-saving and life-sustaining medications.

Share article on social media or email:

Highly Regarded Pediatric Neurologist, Dr. Brian Tseng, Joins NDA Partners as Expert Consultant


News Image

Dr. Tseng’s extensive experience in global clinical development, gene therapy and orphan/accelerated drug development for small and large molecules, in addition to cell and AAV delivered gene modalities will be valuable to companies developing therapies for pediatric patients.

NDA Partners’ General Manager, Eric Fish, announced today that Brian Tseng, MD, PhD, a board-certified pediatric neurologist and neuromuscular specialist with more than 12 years of pharmaceutical industry experience, has joined the company as an Expert Consultant. Dr. Tseng’s experience includes translational medicine, global clinical development, regulatory submissions, health authority interactions, first-in-human and first-in-pediatric clinical studies, gene therapy and orphan/accelerated drug development for small and large molecules and cell and AAV delivered gene modalities including CRISPR-mediated gene editing.

Dr. Tseng was formerly Vice President, Global Head of Clinical Development Neurology, Vertex Cell and Gene Therapy, where he was responsible for leading a cross-functional expert team to oversee all cell and gene therapy efforts in rare neurological disorders including Duchenne Muscular Dystrophy among other rare neurologic indications. Prior to Vertex, he was Vice-President and Global Head of the Pediatrics Therapeutic Area and Pediatric Center of Excellence with Novartis Pharmaceuticals. He has also served on the faculties of University of Colorado Health Sciences Center and Massachusetts General Hospital, Harvard Medical School.

Dr. Tseng serves as an Adjunct Faculty for the University of California San Francisco, American Course on Drug Development and Regulatory Sciences (ACDRS) and co-chaired the 2017 ACDRS workshop on pediatric drug development. According to Dr. Carl Peck, Manager of NDA Partners’ drug development practice and co-founder of the ACDRS program, “Dr. Tseng’s extensive experience in global clinical development, gene therapy and orphan/accelerated drug development for small and large molecules, in addition to cell and AAV delivered gene modalities will be valuable to companies developing therapies for pediatric patients. We are very pleased to welcome him to NDA Partners.”

Dr. Tseng earned his MD and PhD in molecular biology from the University of Texas Houston McGovern School of Medicine/MD Anderson Cancer Center. He earned a master’s degree in physiological science from the University of California, Los Angeles and bachelor’s degree in physiology from the University of California, Berkeley. He completed his residency in pediatrics at the University of Colorado, The Children’s Hospital and his residency in child neurology at the University of California, San Francisco.

About NDA Partners

NDA Partners, a ProPharma Group company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.

Contact

Eric Fish, General Manager

Office: 540-738-2550

FishEric@ndapartners.com

Share article on social media or email:

MD Revolution Joins the Inc. 5000 for the 2nd Year, Ranking No. 3610


MD Revolution, Inc. logo

MD Revolution, Inc.

Inclusion on the Inc. 5000 for the second consecutive year is a testament to the strength of our team and our partners, who are pioneering the future of healthcare through Remote Patient Monitoring, both as a full-service offering and as Software as a Service. -Kyle Williams, CEO

The most prestigious ranking of the fastest-growing private companies in America, Inc. 5000, reveals MD Revolution as a second-time honoree, coming in at No. 3610. The list represents a one-of-a-kind look at the most successful companies within the economy’s most dynamic segment—its independent businesses. The companies on the 2022 Inc. 5000 have not only been successful, but have also demonstrated resilience amid supply chain woes, labor shortages, and the ongoing impact of COVID-19.

“We are incredibly honored to join the ranks of Inc. 5000’s fastest-growing private companies in America for the second year in a row; a testament to our team and partners who are pioneering the future of healthcare,” said Kyle Williams, Chief Executive Officer at MD Revolution. “In 2021, we were ready to deliver Medicare’s Remote Patient Monitoring initiatives, because virtual care management solutions have been our foundation for the past decade. Our dedicated care teams and a deeply integrated technology stack met the demand for a full-service solution from forward thinking healthcare providers. In addition, we launched a Software as a Service (SaaS) offering of our technology, RevUp, to allow organizations with sufficient care management resources to scale their virtual care management programs. We expect our full-service and SaaS solutions to continue to drive growth that resulted in our 2021 Inc. 5000 ranking. Recognition on the Inc. 5000 list for the second time is not only an honor, but also an opportunity to drive awareness of the revolutionary virtual care technology available to practices, hospitals, and health systems nationwide.”

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at http://www.inc.com/inc5000. The top 500 companies are featured in the September issue of Inc. magazine, which will be available on August 23.

“The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work, and rising to the challenges of today.”

“We’ve accelerated a 21st-century health care experience to over 100,000 patients, and we’re confident our capabilities will scale to all the innovative health care providers in America,” said Kyle Williams. “Our goals are clear: to create more health care delivery capacity and to drive better patient outcomes. I’m confident we will continue to augment the traditional medical practice with effective integrations and partnerships to connect patients and providers.”

About MD Revolution

MD Revolution is an innovative Care Management company delivering comprehensive programs for Chronic Care Management, Remote Patient Monitoring, and more. Our solutions uniquely combine integrated technology, clinical care services, and analytics to produce scalable, high touch care models that enrich the patient-provider experience, reduce the cost of care, and generate practice revenue. Our care management platform brings best in class tools to proactively plan ongoing care, engage directly with patients through web and mobile applications, and provide compliance and billing operations. Solutions are available as turn-key solutions, software-as-a-service, and through reseller partners.

More about Inc. and the Inc. 5000

Methodology

Companies on the 2022 Inc. 5000 are ranked according to percentage revenue growth from 2018 to 2021. To qualify, companies must have been founded and generating revenue by March 31, 2018. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2021. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2018 is $100,000; the minimum for 2021 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places. The top 500 companies on the Inc. 5000 are featured in Inc. magazine’s September issue. The entire Inc. 5000 can be found at http://www.inc.com/inc5000.

About Inc.

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference & Gala is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit http://www.inc.com.

CONTACT: Haley Exum

Haley.exum@mdrevolution.com

Share article on social media or email:

Intelerad Acquires PenRad Technologies, Inc., Expanding Breast Imaging and Lung Screening Capabilities


News Image

As our company heads into this next chapter, I’m excited to partner with Intelerad to further grow, scale, and impact patient lives and the healthcare industry at large.

Intelerad Medical Systems™, a leading global provider of enterprise medical imaging solutions, today announced its acquisition of PenRad Technologies, Inc. (PenRad), a software provider for enhancing productivity for breast imaging and lung screening. The acquisition will expand Intelerad’s product offerings for mammography and lung analytics, optimizing workflows for radiologists and boosting health outcomes for patients.

Founded in 1995, PenRad’s three core product offerings – PenRad for breast imaging, PenLung for lung screening, and PenTrac for patient tracking and reporting – have a proven track record of eliminating overhead costs, decreasing liability exposure and increasing patient satisfaction for innovative enterprise systems and diagnostic imaging centers and facilities. With the company’s next-generation technology and dedicated client support, PenRad is leading the way in automated diagnostic radiology.

“Cancer affects all of us, whether you’ve personally been diagnosed or have witnessed a family member, friend or loved one suffer from the disease. PenRad was founded to help drive actionable change for not only my own family’s breast cancer, but for millions of other individuals,” said Greg Gustafson, Founder and President of PenRad. “As our company heads into this next chapter, I’m excited to partner with Intelerad to further grow, scale, and impact patient lives and the healthcare industry at large.”

Notably, the mammography market is expected to increase by more than 20% in the next several years, while the lung cancer diagnostics market is expected to reach $3.4 billion by 2026. PenRad is at the front lines of care as demand surges.

Cancer screenings, and most notably, mammograms, drastically decreased during the COVID-19 pandemic as many healthcare facilities were temporarily closed and others faced severe staffing shortages. As the demand for scans continues to rise to pre-pandemic levels, innovative tools and technologies are critical to ensuring providers can meet the influx of patients, and that such screenings and scans are readily available to further improve overall health outcomes.

“The acquisition of PenRad is an exciting milestone for Intelerad. Our global team of dreamers and doers are committed to improving healthcare through innovative technology, which means delivering the best-in-class systems our industry needs to improve the overall health of all populations,” said Mike Lipps, CEO, Intelerad. “Lung and breast cancer impact millions of individuals, and screenings play a major role in saving lives. By integrating PenRad’s core solutions into our company, we can ensure all patients have access to the scans they need to decrease health risks, while at the same time offering healthcare systems greater productivity.”

This acquisition follows Intelerad’s recent investment by TA Associates. As global demand for scalable imaging and workflow solutions continues to increase, Intelerad will continue to fulfill its mission of providing clients with one of the most scalable imaging platforms in the world, enabling them to drive clinical efficiency and focus on providing enhanced patient care.

For more information on the company and its solutions, including the Enterprise Imaging and Informatics Suite, visit intelerad.com or follow the company on its LinkedIn and Twitter social channels at @Intelerad.

About PenRad

PenRad, a software provider for enhancing productivity for: breast imaging – PenRad, LDCT lung screening – PenLung, general radiology – PenAlert, genetic analysis – PenGen. PenRad invests in diagnostic technology, techniques and analysis in the healthcare community. PenRad provides software, and leadership towards standardization. These include HL7 workgroups, Clinical Interoperability Modeling Initiative (CIMI), and the Cancer-Interoperability project supported by the ONC, FDA, CDC, NCI, NIH and RSNA.

About Intelerad

Intelerad is one of the leading providers of medical imaging software and services for the healthcare industry. Headquartered in Raleigh, NC and Montreal, Intelerad has over 850 employees located in offices across six countries. Nearly 2,000 healthcare organizations around the world rely on Intelerad products to manage patient data, helping them reduce time and workload while improving patient outcomes. Intelerad’s award-winning enterprise imaging solutions have been recognized globally by KLAS, with Intelerad’s Ambra Health ranked #1 for Image Exchange in the 2022 Best in KLAS: Software and Professional Services report. To learn more, visit intelerad.com.

Share article on social media or email:

Homebuyers Flock to Florida for New Developments with Health and Safety Amenities


Serena By the Sea | Valor Capital

“We have taken a proactive approach to this shift in the health of properties,” says Moises Agami, Chairman & CEO of Valor Capital. “All of our properties being built since the pandemic are designed from the ground up with unprecedented standards of health and wellness living in mind.”

Americans were alarmed on July 21, 2022, when the White House announced that President Biden had contracted COVID-19.1 The President, who is fully vaccinated, had previously evaded the virus. He recovered without complications, but his situation spotlights the highly infectious nature of the latest COVID-19 variant.

The pandemic inspired many Americans to relocate to communities with robust outdoor social and entertainment options. The rise of telework gave people unprecedented flexibility in choosing a location for their home base. This led to a Florida real estate explosion as people migrated from the Northeast and other regions. Home sales have been steadily rising as new residents flock to the Sunshine State.2 To meet this demand, VALOR Capitol is designing new multi-unit communities that meet the demand for luxury living alongside risk reduction measures.

“We have taken a proactive approach to this shift in the health of properties,” says Moises Agami, Chairman & CEO of Valor Capital. “All of our properties being built since the pandemic, such as Serena by the Sea, are designed from the ground up with unprecedented standards of health and wellness living in mind.”

COVID Risk Remains High

Unfortunately, new and old Floridians face a heightened risk of contracting COVID-19 as the BA.5 variant sweeps across the state. Case counts started rising in the spring, and, as of August 9, 2022, more than 8,000 new cases have been reported each day.3For residents of multi-unit dwellings, shared spaces and common ventilation systems create concerns about COVID-19 transmission.

Communities Consider Health Impacts

VALOR’s luxury living communities offers striking architectural designs reflecting opulence and quality as well as innovative approaches to indoor air quality to maximize health and safety, including:


  • Each unit is equipped with non-traditional individual fresh air intake 24 hours a day; Residents do not share air with anyone else
  • At all times, an official “How to Stay Well” protocol is in effect, as well as an emergency protocol ready to be put in place in case of a health crisis
  • Polarized media electronic air filters are equipped in all common areas, an enormous improvement on traditional flat filters
  • UV-disinfecting lights that kill an average of 99.9% of germs are equipped in all common areas HVAC units
  • State-of-the-art water filtration system keep the pool and jetted spa pristine
  • EPA-approved human and pet-friendly cleaning products (which have also been proven to kill 99% of tested viruses) are used by maintenance crew in all common areas
  • Touchless door entry systems to guide residents from the entrance to their front doors
  • As well as highly efficient LED lighting, powered by on-site solar panels, illuminating all common areas

“Well-being is more than a way of life from now on—it’s part of the very architecture itself,” as Agami explains. “We will always put health first and foremost, even providing an emergency protocol ready to be put in place in case of another health crisis.”

Although almost sold out, VALOR Capital has a few remaining units in its latest Clearwater-Dunedin area luxury development, Serena by the Sea. The boutique property offers unprecedented elegance, quality, style, and attention to health, safety, and comfort. To learn more about VALOR Capital’s luxury condominium design, visit the website at https://valorc.com/

About Valor Capital

Valor Capital is a team of entrepreneurs passionate about creating world-class real estate experiences. They are an affiliate: a new venture spinoff of international development firm, Terra Capital Partners SA de CV (Terra Capital Partners). With a four-decade history of real estate developments in office, hospitality, medical, commercial and luxury residential product offerings—and a multi-billion-dollar portfolio and tens of millions of square feet already developed and sold—Valor’s developments are always on the cutting-edge, with proprietary anti-viral engineering design used throughout the firm’s newest developments. Visit http://www.valorc.com

References:

1.    NPR. President Biden again tests negative for COVID, ends isolation. August 2022, npr.org/2022/08/06/1115617781/president-biden-has-tested-negative-for-covid-again-but-will-remain-isolation

2.    Tampa Bay Times. Housing bubbles have hit Florida hard. Is it ready for another one? April 2022, tampabay.com/news/real-estate/2022/04/20/housing-bubbles-have-hit-florida-hard-is-it-ready-for-another-one/

3.    New York Times. Tracking Coronavirus in Florida: Latest Map and Case Count. August 2022, nytimes.com/interactive/2021/us/florida-covid-cases.html

Share article on social media or email:

An In-Depth Look into Oncology Trials, Upcoming Webinar Hosted by Xtalks


featured speaker will share efficient clinical trial design strategies that expedite the development of oncology drugs and biologics and how leveraging technology is necessary for navigating today’s drivers of change

Planning and optimizing complex clinical trials in oncology is challenging in an increasingly fast-paced environment. Knowing and understanding adaptive trial designs and master protocols such as basket, umbrella and platform trials, is critical toward accelerating clinical research.

In this webinar, endpoint’s featured speaker will share efficient clinical trial design strategies that expedite the development of oncology drugs and biologics and how leveraging technology is necessary for navigating today’s drivers of change.

Join this webinar to learn more about planning complex clinical trials in oncology.

Join Cat Hall, VP Data and Quality, endpoint Clinical, for the live webinar on Thursday, September 01, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Key Considerations for Planning Complex Clinical Trials: An In-Depth Look into Oncology Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Discussing the Concerns within Clinical Research in Oncology and In-Home Healthcare, Upcoming Webinar Hosted by Xtalks


In-home care also helps a patient go home sooner after intensive treatments like CAR T therapy.

For cancer patients, clinical trials are a necessary care option and often the only piece of hope left when standard-of-care treatments fail. Unfortunately, less than five percent of cancer patients currently participate in clinical trials, though more than 70 percent could benefit from an oncology clinical trial. To close this gap, a model that provides more cancer patients the option to participate needs to be created. In this webinar, the featured speakers discuss concerns in clinical research in oncology and in-home clinical trial care.

One solution in ensuring more cancer patients have access and ability to participate in a clinical trial, is to offer in-home visits as part of the clinical trial. Having the option to be cared for at home where possible — in-between or as part of the protocol required visits — decreases the burden of traveling to a site. In addition, it minimizes the stress involved in the logistics of an already burdensome life with frequent visits for complete care. In-home care also helps a patient go home sooner after intensive treatments like CAR T therapy.

Although the benefits of in-home healthcare are undisputed, the logistics and liabilities associated with providing in-home trial support to cancer patients do create new problems that need to be solved. It is important to ensure critical data are collected for the trial in a new way.

Technology is one of the best ways to ensure these data can be collected from the home trial visit. The speakers will discuss technology solutions that will make in-home healthcare more accessible to patients.

Join this webinar to learn how in-home healthcare can become a more viable care option for more cancer patients.

Join Esther Howard, Oncology Advisor, THREAD Research; Chris Watson, Director, Consulting, THREAD Research; and Todd McGrath, Senior Vice President, Portfolio Delivery, MRN, for the live webinar on Tuesday, August 30, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Discussing the Concerns within Clinical Research in Oncology and In-Home Healthcare.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

For the 7th Time, Aeroflow Healthcare Appears on the Inc. 5000, Ranking No. 4493 With a Three Year Revenue Growth Rate of 98 Percent


News Image

Today, Inc. revealed that Aeroflow Healthcare is No. 4493 on its annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. The list represents a one-of-a-kind look at the most successful companies within the economy’s most dynamic segment—its independent businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

“It’s a great honor to be recognized by Inc. Magazine’s annual list of America’s Fastest-Growing Private Companies for the seventh time,” said Casey Hite, CEO of Aeroflow Healthcare. “One strategy that has set us apart is focusing on our patient journey. Our job doesn’t just end when the equipment shows up at the patient’s doorstep. We continue pushing the limits of what we can offer each patient through ongoing education and customer support”

The companies on the 2022 Inc. 5000 have not only been successful, but have also demonstrated resilience amid supply chain woes, labor shortages, and the ongoing impact of Covid-19. Among the top 500, the average median three-year revenue growth rate soared to 2,144 percent. Together, those companies added more than 68,394 jobs over the past three years.

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at http://www.inc.com/inc5000. The top 500 companies are featured in the September issue of Inc. magazine, which will be available on August 23.

“The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work, and rising to the challenges of today.”

More about Inc. and the Inc. 5000

Methodology

Companies on the 2022 Inc. 5000 are ranked according to percentage revenue growth from 2018 to 2021. To qualify, companies must have been founded and generating revenue by March 31, 2018. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2021. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2018 is $100,000; the minimum for 2021 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places. The top 500 companies on the Inc. 5000 are featured in Inc. magazine’s September issue. The entire Inc. 5000 can be found at http://www.inc.com/inc5000.

About Inc.

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference & Gala is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit http://www.inc.com.

For more information on the Inc. 5000 Conference & Gala, visit http://conference.inc.com/.

About Aeroflow Healthcare

Aeroflow Healthcare is recognized as one of the nation’s leading consumer-driven healthcare companies. Aeroflow provides innovative home healthcare solutions that allow patients to spend more time in their home while lowering healthcare costs and improving quality of life. As a durable medical equipment supplier, Aeroflow works closely with customers and their insurance provider to ensure maximum coverage or find the lowest price possible. The company’s divisions supply equipment for sleep, urology, incontinence, mom and baby, and CGM care. Aeroflow Healthcare provides a large variety of high-quality, affordable medical supplies online to help maintain freedom and peace of mind.

Share article on social media or email:

Codoxo Empowers Healthcare Organizations to Identify and Avoid Fraud With Monthly Forensic AI Alerts


Codoxo Empowers Healthcare Organizations With Monthly Forensic AI Alerts

“Our Forensic AI Alerts allow us to consistently share the timeliest facts and most urgent recommendations on healthcare fraud and abuse topics that have the real potential to negatively impact healthcare plans and others in the healthcare ecosystem.”

Codoxo, a trusted provider of healthcare artificial intelligence solutions, today announced its Forensic AI Alert Series, a monthly report that empowers healthcare cost containment and payment integrity teams to identify and manage rapidly emerging fraud schemes that increase financial risk. Research shows that three-quarters of healthcare executives say that cost containment is a high priority for them in 2022 and more than a third (37%) say it’s their top focus.

Codoxo’s Forensic AI Alerts are developed by a team of payment integrity and fraud, waste, and abuse (FWA) experts. They cover critical fraud updates, data mandates, and coding changes that are difficult for internal SIU and payment integrity teams to track while providing best practices and specific steps on how to act upon them. Topics covered include:


  • New and emerging schemes to watch
  • Code updates – procedure, diagnosis, evaluation, especially those that could be ripe for fraud
  • Coverage criteria updates
  • Supplemental references

“Our Forensic AI Alerts allow us to consistently share the timeliest facts and most urgent recommendations on healthcare fraud and abuse topics that have the real potential to negatively impact healthcare plans and others in the healthcare ecosystem,” said Rena Bielinski, PharmD, AHFI, Codoxo VP of Customer Success. “Healthcare leaders are craving more knowledge about ways to better manage costs and avoid fraud and waste, but often find it challenging to track and monitor that information themselves. We’re dedicated to helping our customers do just that every day.”

The alerts have already proved valuable in addressing ongoing concerns across many emerging areas of COVID-19, including:

  • Vaccination status diagnosis codes
  • Latest testing guidelines
  • Vaccine and administration codes
  • Post COVID-19
  • Telehealth

“Codoxo continues to disrupt the status quo of rising healthcare costs while providing continuous learning opportunities to our community of payment integrity and FWA experts,” said Musheer Ahmed, founder and CEO, of Codoxo. “Our aim is to continue to serve the healthcare industry by providing consistent, timely, and informative updates.”

Click here to view the latest Forensic AI Alerts from Codoxo.

About Codoxo

Codoxo’s mission is to make healthcare more affordable and effective for everyone and serves as the premier provider of artificial intelligence-driven solutions and services that help healthcare companies and agencies proactively detect and reduce risks from fraud, waste, and abuse. The Codoxo Healthcare Integrity Suite helps clients manage costs and improve collaboration across payment integrity, special investigation units, provider coding, and billing, network management, and clinical care teams. Codoxo’s software-as-a-service applications are built on their proven Forensic AI Platform, which uses patented AI-based technology to identify problems and suspicious behavior faster and earlier than other AI and rule-based techniques. All solutions are HIPAA- compliant and operate in a HITRUST-certified environment. For additional information, visit http://www.codoxo.com.

Share article on social media or email: